MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:41 am
Share
MEDIPOST Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 17,419.47 million compared to KRW 16,323.5 million a year ago. Net loss was KRW 2,806.95 million compared to net income of KRW 15,998.61 million a year ago. Basic loss per share from continuing operations was KRW 138 compared to basic earnings per share from continuing operations of KRW 991 a year ago. Diluted loss per share from continuing operations was KRW 138 compared to diluted earnings per share from continuing operations of KRW 991 a year ago. Basic loss per share was KRW 138 compared to basic earnings per share of KRW 991 a year ago.
For the nine months, sales was KRW 4,160.16 million compared to KRW 4,085.9 million a year ago. Net loss was KRW 5,544.82 million compared to KRW 1,886.6 million a year ago. Basic loss per share from continuing operations was KRW 316 compared to KRW 117 a year ago. Diluted loss per share from continuing operations was KRW 316 compared to KRW 117 a year ago. Basic loss per share was KRW 316 compared to KRW 117 a year ago.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
